NSI‐566 is a stable, primary adherent neural stem cell line derived from a single human fetal spinal cord and expanded epigenetically with no genetic modification. This cell line is being tested in clinical trials in the U.S. for treatment of amyotrophic lateral sclerosis and spinal cord injury. In a single‐site, phase I study, we evaluated the feasibility and safety of NSI‐566 transplantation for the treatment of hemiparesis due to chronic motor stroke and determined the maximum tolerated dose for future trials. Three cohorts (n = 3 per cohort) were transplanted with one‐time intracerebral injections of 1.2 × 107, 2.4 × 107, or 7.2 × 107 cells. Immunosuppression therapy with tacrolimus was maintained for 28 days. All subjects had sustained chronic motor strokes, verified by magnetic resonance imaging (MRI), initiated between 5 and 24 months prior to surgery with Modified Rankin Scores [MRSs] of 2, 3, or 4 and Fugl‐Meyer Motor Scores of 55 or less. At the 12‐month visit, the mean Fugl‐Meyer Motor Score (FMMS, total score of 100) for the nine participants showed 16 points of improvement (p = .0078), the mean MRS showed 0.8 points of improvement (p = .031), and the mean National Institutes of Health Stroke Scale showed 3.1 points of improvement (p = .020). For six participants who were followed up for 24 months, these mean changes remained stable. The treatment was well tolerated at all doses. Longitudinal MRI studies showed evidence indicating cavity‐filling by new neural tissue formation in all nine patients. Although this was a small, one‐arm study of feasibility, the results are encouraging to warrant further studies. Stem Cells Translational Medicine 2019
Glioblastoma (GBM) is classified into subtypes according to the molecular expression profile; the proneural subtype has a relatively good prognosis, and the mesenchymal type is the most aggressive form with the worst prognosis. GBM undergoes proneural–mesenchymal transition (PMT) during its evolution or in response to changes in the microenvironment or therapeutic interventions. PMT is accompanied by infiltration of non-tumor cells, decreased tumor purity, and immune evasion. However, the cellular and molecular mechanisms underlying PMT remain unclear. Differentially expressed genes (DEGs) were identified using GBM transcriptome datasets, and prognostic analysis was performed to screen for PMT-related genes (PMTRGs). Consensus cluster analysis was followed by Gene Set Enrichment Analysis, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analyses of DEGs to determine the biological functions and pathways regulated by PMTRGs. CIBERSORT, TIMER, MCPCOUNTER, and XCELL algorithms were used to analyze immune cell infiltration patterns. The TIDE algorithm was used to examine immunotherapy scores. The Lasso, Cox, and Step machine learning algorithms were used to construct and screen the optimal risk assessment prognostic model. PMTRG expression patterns in patient tissues and different cell subsets were examined by proteomics and single-cell transcriptome data analysis. Seventeen DEGs and prognostic PMTRGs were identified in proneural and mesenchymal subtypes. PMTRG-related mRNA interactions and protein–protein interaction networks were associated with the immune activity of GBM. Consensus cluster analysis based on PMTRGs divided GBM into three independent subclusters. Functional and pathway analyses showed that PMTRGs were highly expressed in the C1 subcluster, which was associated with GBM mesenchymal isoforms, pathways, and poor prognosis, and showed stronger immune responses. Four immune evaluation algorithms and TIDE analysis showed that the C1 cluster had high levels of immune cell infiltration and immune molecule scores. The prognostic risk assessment model based on PMTRGs can effectively predict the prognosis of GBM patients. Proteomic data from immunohistochemistry and single-cell transcriptome data suggested that PMTRGs are predominantly expressed in monocytes, macrophages, and blood vessels rather than in tumor cells. This study identified 17 key genes associated with PMT in GBM. These PMTRGs are mainly expressed on immune cells and blood vessels in the GBM microenvironment and are associated with poor prognosis, suggesting that PMT events mainly arise from the infiltration and activation of immune cells derived from the bone marrow and blood vessels. These findings provide new evidence and targets for the treatment of GBM.
To confirm whether machine learning algorithms (MLA) can achieve an effective risk stratification of dying within 7 days after basal ganglia hemorrhage (BGH). We collected patients with BGH admitted to Sichuan Provincial People’s Hospital between August 2005 and August 2021. We developed standard ML-supervised models and fusion models to assess the prognostic risk of patients with BGH and compared them with the classical logistic regression model. We also use the SHAP algorithm to provide clinical interpretability. 1383 patients with BGH were included and divided into the conservative treatment group (CTG) and surgical treatment group (STG). In CTG, the Stack model has the highest sensitivity (78.5%). In STG, Weight-Stack model achieves 58.6% sensitivity and 85.1% specificity, and XGBoost achieves 61.4% sensitivity and 82.4% specificity. The SHAP algorithm shows that the predicted preferred characteristics of the CTG are consciousness, hemorrhage volume, prehospital time, break into ventricles, brain herniation, intraoperative blood loss, and hsCRP were also added to the STG. XGBoost, Stack, and Weight-Stack models combined with easily available clinical data enable risk stratification of BGH patients with high performance. These ML classifiers could assist clinicians and families to identify risk states timely when emergency admission and offer medical care and nursing information.